2020 Immunity Vaccines 
pharmaphorum
FEBRUARY 9, 2022
In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. over the last five years. A broad front.
pharmaphorum
JUNE 21, 2021
It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot. Among the 25-strong group given the vaccine on its own, there was one patient who had a complete remission of tumours that had spread from the original site.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
AUGUST 16, 2022
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated version of Moderna’s COVID-19 vaccine, Spikevax, that targets two coronavirus variants as a booster. The regulator confirmed that the vaccine meets its standards of safety, quality and effectiveness. 1) and the original 2020 strain.
Express Pharma
APRIL 7, 2023
People exposed to higher levels of air pollution before the pandemic had lower antibody responses to COVID-19 vaccines, according to a study. The findings, published in the journal Environmental Health Perspectives , provide further evidence on the adverse effects of air pollution on the immune system. Exposure to PM2.5,
Express Pharma
OCTOBER 16, 2024
Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800 per cent increase in licensing agreement deal values from 2019 to 2024YTD, driven by the remarkable success of mRNA vaccines during the COVID-19 pandemic. GSK and CureVac restructured their 2020 collaboration into a new licensing agreement worth up to $1.57
European Pharmaceutical Review
AUGUST 2, 2023
A new COVID-19 vaccine has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Bimervax is now the ninth vaccine to be authorised by the UK’s independent medicines regulator to treat the virus. This is an additional ingredient designed to trigger a stronger immune response.
European Pharmaceutical Review
JULY 11, 2022
The novel coronavirus vaccine has been developed at Caltech and The University of Oxfor d. Funding of up to $30 million will support vaccine design, its development through Phase I trials and regulatory activities. . The novel vaccine, which is based on mosaic?8 How the novel coronavirus vaccine works. The novel vaccine?is
Expert insights. Personalized for you.
134 
Let's personalize your content